Acting FDA chief Janet Woodcock defended FDA’s efforts to respond to the opioid epidemic, while also saying opioid overprescribing is still a problem that requires a change in prescriber behavior. But former FDA official Josh Sharfstein said there’s more FDA could do to respond to the crisis, including by making opioid use disorder treatments, like methadone and buprenorphine, more accessible, and increasing transparency around its opioid risk mitigation plans. Woodcock and Sharfstein made their comments during separate pre-recorded interviews posted...